# To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC

> **NCT05169801** · PHASE3 · COMPLETED · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 520 (actual)

## Conditions studied

- Non-small Cell Lung Cancer(NSCLC)

## Interventions

- **DRUG:** BP102, paclitaxel, carboplatin
- **DRUG:** Avastin®, paclitaxel, carboplatin

## Key facts

- **NCT ID:** NCT05169801
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-25
- **Primary completion:** 2019-10-21
- **Final completion:** 2021-06-17
- **Target enrollment:** 520 (ACTUAL)
- **Last updated:** 2021-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05169801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05169801, "To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05169801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*